Table 1.
Expression of NQO1 and clinically relevant proteins in non-small cell lung carcinoma patients with and without KRAS mutations.
| Protein | IHC a | KRAS Wild Type b | KRAS Mutated b | Total | P c |
|---|---|---|---|---|---|
| NQO1 | Negative | 17 | 2 | 19 | <0.001 * |
| Positive | 16 | 24 | 40 | ||
| DNMT1 | Negative | 14 | 1 | 15 | <0.001 * |
| Positive | 19 | 25 | 44 | ||
| DNMT3a | Negative | 24 | 10 | 34 | 0.01 * |
| Positive | 10 | 16 | 26 | ||
| ERK1/2 | Negative | 17 | 11 | 28 | 0.002 * |
| Positive | 4 | 20 | 24 | ||
| c-MET | Negative | 5 | 9 | 14 | 0.43 |
| Positive | 15 | 16 | 31 | ||
| Survivin | Negative | 3 | 10 | 13 | 0.19 |
| Positive | 19 | 20 | 39 |
a IHC = results of the immunohistochemical staining. b Values in these columns represent numbers of patients with positive or negative immunohistochemical staining. c An asterisk “*” denotes statistical significance at P = 0.05.